@article {Au970, author = {Adrian Au and Vishal S Parikh and Rishi P Singh and Justis P Ehlers and Alex Yuan and Aleksandra V Rachitskaya and Jonathan E Sears and Sunil K Srivastava and Peter K Kaiser and Andrew P Schachat and Daniel F Martin and Yasha Modi}, title = {Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration}, volume = {101}, number = {7}, pages = {970--975}, year = {2017}, doi = {10.1136/bjophthalmol-2016-309434}, publisher = {BMJ Publishing Group Ltd}, abstract = {Background The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD).Methods This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive. Diagnosis was confirmed retrospectively by fluorescein angiography and spectral-domain optical coherence tomography. Exclusion criteria included serous/drusenoid PEDs or patients who switched anti-VEGF. Mean follow-up across all therapies was 313.9{\textpm}85.3 days.Results Average age of all patients was 80.6 years. Baseline maximum subfoveal PED height was 326.8{\textpm}185.1 μm, 394.5{\textpm}238.6 μm and 258.0{\textpm}145.3 μm for bevacizumab, aflibercept and ranibizumab, respectively (p=0.05). All patients had subretinal fluid, intraretinal fluid or a combination of the two at an initial presentation. Central retinal thickness decreased at all time points compared with baseline across all three anti-VEGF therapies. Subfoveal PED height decreased in patients treated with aflibercept at all time points and decreased in patients treated with bevacizumab at 1-month, 3-month and 6-month time points. Aflibercept reduced PED height more than bevacizumab at 1-month and 12-month follow-ups (p=0.02 and p=0.03, respectively) and ranibizumab at 1-month and 6-month follow-ups (p=0.03 and p=0.02, respectively). No differences in best-corrected visual acuity were appreciated at any time point between drugs.Conclusions There was a significant reduction in subfoveal PED height for aflibercept and bevacizumab compared with baseline. A direct comparison of drugs demonstrated a beneficial reduction of PED height, albeit inconsistently, favouring aflibercept. There were no differences in visual acuity across the groups at any time point.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/101/7/970}, eprint = {https://bjo.bmj.com/content/101/7/970.full.pdf}, journal = {British Journal of Ophthalmology} }